Physician profile
Kimball E Ewell
NPI 1457303943
$4,010.70
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $582 · 2021: $1,087 · 2022: $929 · 2023: $520 · 2024: $31.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $891.12 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $457.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $319.53 | 2019-2023 | |
| Lilly USA, LLC | $274.23 | 2019-2023 | Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $261.66 | 2019-2022 | |
| Amgen INC. | $246.16 | 2019-2022 | |
| Abbvie INC. | $224.36 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.23 | 2020-2022 | |
| Glaxosmithkline, LLC. | $168.75 | 2021-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Vanda Pharmaceuticals INC. | $135.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $131.15 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbott Laboratories | $87.42 | 2021-2023 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $86.22 | 2019-2023 | Eliquis |
| Astellas Pharma US INC | $82.48 | 2019-2021 | |
| Dexcom, INC. | $79.97 | 2021-2024 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $67.79 | 2019-2024 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.07 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $44.85 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $41.34 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $39.85 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $35.89 | 2021 | |
| Genentech USA, INC. | $27.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.80 | 2019 | |
| Amarin Pharma, INC. | $15.64 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.17 | 2020 | |
| Esperion Therapeutics, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimball Ewell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.